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Abstract
Background: Ovarian cancer constitutes one of the most lethal gynecologic malignancies for females. Currently,
early detection strategies and therapeutic options for ovarian cancer are far from satisfactory, leading to high
diagnosis rates at late stages and disease relapses. New avenues of therapy are needed that target key processes in
ovarian cancer progression. While a variety of non-coding RNAs have been proven to regulate ovarian cancer
metastatic progression, the functional roles of RNA-binding proteins (RBPs) in this process are less well defined.
Results: In this study, we identify that the RBP sorbin and SH3 domain containing 2 (SORBS2) is a potent
suppressor of ovarian cancer metastatic colonization. Mechanistic studies show that SORBS2 binds the 3′
untranslated regions (UTRs) of WFDC1 (WAP four-disulfide core domain 1) and IL-17D (Interleukin-17D), two secreted
molecules that are shown to act as metastasis suppressors. Enhanced expression of either WFDC1 or IL-17D potently
represses SORBS2 depletion-mediated cancer metastasis promotion. By enhancing the stability of these gene
transcripts, SORBS2 suppresses ovarian cancer invasiveness and affects monocyte to myeloid-derived suppressor cell
and M2-like macrophage polarization, eliciting a tumor-suppressive immune microenvironment.
Conclusions: Our data illustrate a novel post-transcriptional network that links cancer progression and
immunomodulation within the tumor microenvironment through SORBS2-mediated transcript stabilization.
Keywords: RNA binding protein, SORBS2, Ovarian cancer, Metastasis, mRNA stability, Immunomodulation, WFDC1,
IL-17D
Background
Ovarian cancer has been reported to be the most lethal
among gynecologic malignancies, with over 21,000 pa-
tients diagnosed and more than 14,000 deaths in the
United States in 2014 [1]. The majority of ovarian cancer
histological subtypes are high grade serous ovarian
carcinoma (HGSOC), with relatively poor prognosis due
to the advanced stage of disease at diagnosis, widespread
metastasis, and high relapse rate [2]. However, the mo-
lecular mechanisms that mediate ovarian cancer pro-
gression are far from elucidated, rendering the diagnosis
and treatment of ovarian cancer still unsatisfactory.
Ovarian cancer predominantly metastasizes via pelvic
dissemination directly to adjacent organs instead of
through lymphatic or hematologic channels [3]. Re-
cently, the tumor microenvironment has gradually been
recognized to be critical for ovarian cancer intraperito-
neal metastasis. Interacting with tumor cells via
secretory reciprocal communication, the surrounding
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microenvironment provides a driving force for cancer
cell invasion and metastasis. The stromal cells (including
fibroblasts, macrophages, regulatory T cells, myeloid-
derived suppressor cells, endothelial cells, pericytes, and
platelets), the extracellular matrix (ECM; made of in-
flammatory cytokines, chemokines, matrix metallopro-
teinases, integrins, and other secreted molecules), and
exosomes (small extracellular vesicles loaded with mole-
cules), which make up the tumor microenvironment,
have gained increasing attention due to their vital role in
promotion of ovarian cancer progression [4]. Tumor
cells educate immune cells in the evolution of different
cancer stages [5]. During each step of the metastatic cas-
cade, mutant and thus potentially immunogenic tumor
cells are exposed to the immune system, which can
recognize them and restrict their growth. However,
cancers and their metastatic derivatives could evolve to
overcome these immune mechanisms partly through the
recruitment of immunosuppressive cells and inactivation
of tumor-killing cells [6]. Currently, researchers are fo-
cused on how the immune cells are educated, recruited,
and/or differentiate to promote cancer metastasis. For
instance, Jiménez-Sánchez et al. [7] recently presented
an exceptional case of a patient with high-grade serous
ovarian cancer, treated with multiple chemotherapy regi-
mens, who exhibited regression of some metastatic le-
sions with concomitant progression of other lesions
during a treatment-free period. Through immunoge-
nomic approaches, they found that progressing metasta-
ses were characterized by immune cell exclusion,
whereas regressing and stable metastases were infiltrated
by CD8+ and CD4+ T cells and exhibited oligoclonal ex-
pansion of specific T-cell subsets. They also detected
CD8+ T-cell reactivity against predicted neoepitopes
after isolation of cells from a blood sample taken almost
3 years after the tumors were resected. These findings
suggest that multiple distinct tumor immune microenvi-
ronments co-exist within a single individual and may ex-
plain in part the heterogeneous fates of metastatic
lesions often observed in the clinic post-therapy. More-
over, Montfort et al. [8] recently discovered that B cells
mainly infiltrated lymphoid structures in the stroma of
HGSOC metastases. There was a strong B-cell memory
response directed at a restricted repertoire of antigens
and production of tumor-specific IgGs by plasma cells.
Chemotherapy could further enhance these responses.
These observations highlight the importance of immune
cells in intraperitoneal metastasis. However, currently it
is still unclear whether RNA binding protein (RBP)-
based post-transcriptional regulation of mRNAs could
link ovarian cancer metastasis and immune functions.
In this study, we performed an integrated analysis of a
HGSOC data set and gene profiles of ovarian cancers to
identify key RBPs potentially responsible for ovarian
cancer metastatic colonization. We identified the RBP
sorbin and SH3 domain containing 2 (SORBS2) as a me-
tastasis suppressor in ovarian cancer. More interestingly,
we found that a SORBS2-stablized secretome in ovarian
cancer could condition the tumor microenvironment to
be favorable for cancer metastasis, via affecting the
polarization of monocytes to myeloid-derived suppressor
cells (MDSCs) and M2-like macrophages. Therefore, our
findings characterize a novel post-transcriptional net-
work that links cancer progression and immunomodula-
tion within the tumor microenvironment through
SORBS2-mediated transcript stabilization and could pro-
vide a theoretical rational for the potential clinical appli-
cation value of such therapeutic targets for precision
therapy of individuals with ovarian cancer.
Results
Integrated analysis identifies SORBS2 as a key RBP that
suppresses ovarian cancer metastasis
To identify key RBPs required for ovarian cancer devel-
opment and progression, we cross-referenced a list of
RBPs in the published literature to compile a compre-
hensive list of 1345 genes encoding all known human
RBPs. Public oncogenomic data were analyzed to score
genes based on three properties: (1) lower expression in
tumors versus normal tissues (GSE14407) [9]; (2) down-
regulated in metastasis sites compared with the primary
site of ovarian cancer (GSE30587) [10]; or (3) negative
association with the stem-cell state (GSE53759) [11].
Genes scoring in any of these three categories as well as
those at the top of each category were selected to define
a high-priority set of 145 RBP genes (Fig. 1a and
Additional file 1: Table S1). We searched these 145 RBP
genes in the cBioPortal TCGA ovarian cancer dataset
and examined their amplification and deletion status in
these samples. Among all these RBP genes, only four
showed deletion in more than 5% of TCGA ovarian can-
cer samples, including transcription factor BTF3, sorbin
and SH3 domain-containing protein 2 (SORBS2), cold-
inducible RNA-binding protein (CIRBP), and RNA-
binding protein MEX3D (MEX3D) (Fig. 1b). We next
screened the functional roles of these four RBPs in
ovarian cancer metastasis using a siRNA-mediated RNA
silencing strategy in Transwell chamber analysis. We
found that only SORBS2 and MEX3D gene knock down
significantly increased the metastatic colonization cap-
acity of ovarian cancer (Fig. 1c). Moreover, we searched
the prognostic prediction values of these two genes in
the Australian Ovarian Cancer Study (AOCS) dataset
(GSE9891) and found that only SORBS2 was signifi-
cantly correlated with overall survival of ovarian cancer
patients (Fig. 1d and Additional file 2: Figure S1). In
addition, we performed gene set enrichment analysis
(GSEA) in TCGA and confirmed that genes comprising
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the TGF-β program signature and the cell adhesion pro-
gram signature, two programs widely accepted for their
cancer metastasis regulation role, were both highly
enriched for ovarian cancer samples with differential
SORBS2 expression levels (Fig. 1e), further corroborating
the regulatory role of SORBS2 in ovarian cancer metas-
tasis. These data indicate that SORBS2 could be the key
RBP that suppresses ovarian cancer metastasis.
Fig. 1 Outline of the screening strategy identifying the RBP SORBS2 as a key suppressor of metastatic colonization of ovarian cancer. a Venn diagram
outlining the meta-analysis of key RBPs essential for ovarian cancer aggressiveness. b Genomic alterations of the top scored RBP genes in TCGA ovarian
cancer dataset. c Relative migration ability of ovarian cancer cells treated with siRNAs of four significantly downregulated RBPs in TCGA ovarian cancer
dataset. d Kaplan-Meier analysis of SORBS2 expression and clinical outcome of ovarian cancer in the Australian Ovarian Cancer Study (AOCS) dataset.
e Gene set enrichment analysis (GSEA) plots showing enrichment of the TGF-β program and the cell adhesion program in different genes between
SORBS2 high and SORBS2 low groups in TCGA dataset. Data are shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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SORBS2 expression is associated with clinical outcome of
ovarian cancer patients
We further examined the expression of SORBS2 in dif-
ferent ovarian cancer datasets and found that SORBS2
expression was uniformly down-regulated in ovarian
cancer tissues compared with either normal ovary tissues
or borderline ovarian tumor tissues in four publicly
available datasets (Additional file 2: Figure S2a). More-
over, the expression of SORBS2 in late stage ovarian
cancer patients (FIGO stages III and IV) was also signifi-
cantly reduced compared with early stage ovarian cancer
patients (FIGO stages I and II) in Gilks’ dataset and
Yoshihara’s dataset (Additional file 2: Figure S2b) while
no significant difference was observed in the expression
of BTF3, CIRBP, and MEX3D between primary and meta-
static ovarian tissues in public datasets (Additional file 2:
Figure S3a–c). We next examined the protein expression
level of SORBS2 in clinical specimens of ovarian cancer
and normal ovary using immunohistochemistry analysis.
The results showed that SORBS2 was significantly down-
regulated in ovarian cancer compared with normal ovary
(Additional file 2: Figure S2c). Moreover, we found that
SORBS2 expression was correlated with clinical prognosis
in a West China cohort of ovarian cancer (Additional file
2: Figure S2d), consistent with our findings for the AOCS
dataset. We further validated our findings in CSIOVDB, a
transcriptomic microarray database of 3431 human ovar-
ian cancers that included clinico-pathological parameters
and follow-up information of ovarian cancer patients [12].
We observed in the CSIOVDB database that there was
significant reduction of SORBS2 expression in ovarian tu-
mors compared with normal ovarian surface epithelium
(Additional file 2: Figure S4a). Moreover, CSIOVDB ana-
lysis revealed that SORBS2 expression was significantly
down-regulated in ovarian cancers with higher differenti-
ation degree (Additional file 2: Figure S4b), more advanced
FIGO stage (Additional file 2: Figure S4c), and refractory or
resistant disease (Additional file 2: Figure S4d). Consistent
with the results from the AOCS and West China cohort,
Kaplan-Meier analysis of ovarian cancer patients in
CSIOVDB also showed that SORBS2 expression was corre-
lated with overall survival and progression-free survival of
ovarian cancer patients (Additional file 2: Figure S4e
and Additional file 2: Figure S4f ). Moreover, we fur-
ther analyzed SORBS2 expression with other clinical
parameters that might influence the prognosis of
ovarian cancer patients in the Tothill dataset
(GSE9899) [13], including patient age and disease
stage. We found that SORBS2 expression was lower
in stage I ovarian cancer patients compared with
stage II–IV ovarian cancer patients (Additional file 2:
Figure S5a). A negative correlation between age of
ovarian cancer patients and SORBS2 was also
observed (Additional file 2: Figure S5b).
High grade serous ovarian carcinoma can be classified
into four subtypes—immunoreactive subtype, differenti-
ated subgroup, proliferative subgroup, and mesenchymal
subgroup [14]—among which the mesenchymal sub-
group and the proliferative subtype have poorer prognosis
while the immunoreactive subtype and the differentiated
subtype have better prognosis [13]. Correspondingly, we
have categorized 15 ovarian cancer cell lines into the four
subtypes based upon the classifiers used in TCGA ovarian
cancer dataset (Additional file 3: Table S2). We performed
qRT-PCR to examine the mRNA levels of SORBS2 in
these subgrouped ovarian cancer cell lines. Consistently,
we found that SORBS2 expression was significantly lower
in the group with poorer prognosis (the mesenchymal and
proliferative subtypes) compared with the group with
better prognosis (the immunoreactive and differentiated
subtypes) (Additional file 2: Figure S6a). Moreover, we an-
alyzed the differential expression of SORBS2 in (a) BRCA1
mutant and BRCA2 mutant tumor tissues compared with
wild-type tumor tissues; (b) CCNE1high and CCNE1low
ovarian tumor tissues in TCGA dataset. As shown in
Additional file 2: Figure S6b, c, we found that there is a
trend that the expression of SORBS2 is lower in BRCA1
and BRCA2 mutant (MUT) tissues compared with the
BRCA1 and BRCA2 wild type (WT) specimens, although
no statistical significance was observed (Additional file 2:
Figure S6b, c). Moreover, we found a significant negative
correlation between the expression of SORBS2 and
CCNE1(r = − 0.26, P = 8.666e-07; Additional file 2: Figure
S6d). The expression of SORBS2 in CCNE1high ovarian can-
cer specimens is significantly lower compared with that in
CCNE1low ovarian cancer specimens (Additional file 2:
Figure S6e). These findings indicate that SORBS2 was
closely correlated with clinical outcome of ovarian cancer
patients.
SORBS2 suppresses ovarian cancer metastasis in vitro and
in vivo
We next sought to characterize the cellular phenotypes
altered in cells depleted of SORBS2. We designed two
short-hairpin RNAs (shRNA) to stably silence SORBS2
expression in both SKOV-3 and A2780s ovarian cancer
cells (Fig. 2a and Additional file 2: Figure S7a, b). First,
we did not observe enhanced primary tumor growth
rates in SORBS2 knockdown ovarian cancer cells com-
pared with control cells in vivo (data not shown). There-
fore, the enhanced metastatic colonization potential
exhibited by SORBS2-knockdown cells is independent of
increased proliferation or growth rates. Subsequently, we
examined the metastasis-suppressive role of SORBS2 in
ovarian cancer in vivo. We used an orthotopic model
generated by intrabursal injection in nude mice. The ex-
tent of peritoneal metastasis of ovarian cells was exam-
ined by sacrifice 4 weeks post-inoculation. We observed
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that SORBS2 knockdown significantly promoted in vivo
metastatic colonization of ovarian cancer cells in mice (Fig.
2b), including increasing the number of metastatic nodules
(Fig. 2c) and the ascites volume (Fig. 2d) within the abdom-
inal cavity. Moreover, SORBS2 silencing significantly short-
ened survival of tumor-bearing mice compared with the
control group (Fig. 2e). Immunohistochemical analysis of
Ki-67 in tumor tissues in the control group and the SORBS2
knockdown group did not demonstrate significant difference
(Additional file 2: Figure S8a), indicating that SORBS2
knockdown primarily hijacked metastatic programs instead
of proliferation-related signaling in ovarian cancer. More-
over, we observed a significant decrease in the protein level
of cleaved caspase 3 in the lysed tissues of metastasis in the
SORBS2 knockdown group compared with that in the con-
trol group (Additional file 2: Figure S8b). PI/Annexin V flow
cytometry analysis also revealed that the apoptosis
rate in the metastasized tissues in the SORBS2-
knockdown group was significantly lower than that in
the control group (Additional file 2: Figure S8c), re-
vealing an apoptosis resistance-promoting role of
SORBS2 knockdown in ovarian cancer.
We further examined the cellular phenotype of
SORBS2 depletion in vitro. It was observed that SORBS2
knockdown could induce spindle-like morphology of
A2780s cells compared with the original epithelial pheno-
type (Additional file 2: Figure S8d). Colony formation assay
revealed that knockdown of SORBS2 did not affect in vitro
cellular proliferation rates (Additional file 2: Figure S8e).
Cell cycle analysis by PI staining revealed that while a sig-
nificant decrease in the percentage of cells in sub G0/G1
phage in the SORBS2 knockdown cell lines compared with
control cells, no significant changes were observed in G0/
G1, S, and G2/M phase in both SORBS2 knockdown and
control cells (Additional file 2: Figure S8f). To define the
potential phenotypes displayed by SORBS2-depleted cells
that could enhance metastatic activity in vitro, we assessed
the ability of SORBS2-knocked down ovarian cancer cells
to migrate through Transwell chamber. SORBS2 depletion
significantly enhanced migration ability of both A2780s and
SKOV-3 ovarian cancer cells through Transwell chamber
analysis (Fig. 2f). Consistently, wound healing analysis dem-
onstrated that knockdown of SORBS2 expression in
A2780s and SKOV-3 ovarian cancer cells significantly
Fig. 2 SORBS2 depletion promotes ovarian cancer metastasis. a Western blot analysis for SORBS2 in whole-cell lysate of A2780s cells expressing
either of two independent shRNAs targeting SORBS2 or a control shRNA. b Representative photographs of peritoneal metastasis of A2780s and
SKOV-3 ovarian cancer cells 4 weeks post-inoculation. c Box plot of number of metastatic nodules of tumors in the abdominal cavities. d Box plot
of the ascites volumes collected from the abdominal cavities. e Kaplan-Meier analysis of mice in the orthotopic model generated by intrabursal
injection of either A2780s or SKOV-3 ovarian cancer cells expressing either of two independent shRNAs targeting SORBS2 or a control shRNA. f
Cell migration capacity of SORBS2-depleted A2780s and SKOV-3 ovarian cancer cells compared with control cells was assessed by transwell
analysis. g Cell migration capacity of SORBS2-depleted A2780s and SKOV-3 ovarian cancer cells compared with control cells was assessed by
wound healing analysis. Data are shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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enhanced their metastatic potential (Fig. 2g). These results
reveal that SORBS2 impedes the metastasis capacity of
ovarian cancer cells in vitro. These findings indicate that re-
duced expression of SORBS2 is sufficient to promote ovar-
ian cancer metastatic colonization both in vitro and in vivo.
SORBS2 binds and stabilizes transcripts in ovarian cancer
cells
We subsequently investigated the molecular mechanisms
through which SORBS2 mediates suppression of meta-
static colonization of ovarian cancer. Considering that
SORBS2 belongs to the RBP family, we attempted to
identify its direct targets as potential mediators of its
biological effects. First, to identify endogenous RNA tar-
gets of SORBS2 in ovarian cancer cells, we performed
high-throughput RNA immunoprecipitation sequencing
(RIP sequencing) in A2780s ovarian cancer cell lines ex-
pressing Flag-tagged SORBS2 and control A2780s ovar-
ian cancer cells (Fig. 3a; Additional file 2: Figure S7c and
Additional file 2: Figure S9a–b). Second, considering that
one of the most important functions of RBPs is the regula-
tion of RNA stability, we performed transcriptome-wide
analysis of RNA stability to identify the RNAs that
SORBS2 could stabilize in ovarian cancer metastasis. We
treated SORBS2-depleted or control A2780s ovarian can-
cer cells with α-amanitin and isolated RNA. Relative tran-
script levels were determined through transcriptomic
sequencing, revealing a set of transcripts whose stability
was deregulated upon SORBS2 loss. Next, we asked
whether transcripts directly bound by SORBS2 were sig-
nificantly enriched among transcripts with SORBS2-
dependent changes in stability. Therefore, we compared
the set of SORBS2-bound transcripts (from the RIP-seq
data) along with transcript stability measurements ob-
tained from the transcriptomic profiling of SORBS2 deple-
tion and control cells treated with α-amanitin. We found
that a proportion of transcripts bound by SORBS2 over-
lapped with the group of transcripts destabilized by
SORBS2 knockdown compared with transcripts with no
SORBS2-dependent changes in stability (Fig. 3b). These
data demonstrate that SORBS2 could serve as an enhan-
cer of transcript stability through direct binding of tran-
scripts in ovarian cancer. We next attempted to identify
SORBS2-bound transcripts that could mediate its effects
on ovarian cancer metastasis. As we had observed that
SORBS2-bound transcripts were generally stabilized, we
sought to identify transcripts bound by SORBS2, destabi-
lized by SORBS2 knockdown, and down-regulated at
steady state in SORBS2-depleted cells. Through this ana-
lysis, we identified 91 genes (accounting for 8.39% of all
the transcripts bound by SORBS2) as potential regulators
of ovarian cancer metastasis downstream of SORBS2 (Fig.
3b and Additional file 4: Table S3). Further gene ontology
enrichment analysis of biological processes demonstrated
that these genes are enriched in biological processes such
as regulation of atrial cardiac muscle cell membrane
Fig. 3 SORBS2 depletion affects the stability of transcripts directly bound by SORBS2. a Distribution of SORBS2 RIP sequencing peak annotation
for different regions. b Venn diagram of transcripts stabilized and bound by SORBS2. Transcripts bound by SORBS2 in the RIP sequencing data
(n = 1084), transcripts with steady state levels downregulated in shSORBS2 versus control cells (n = 708; fold change down > 1.1 in shSORBS2
vs shCTRL, q < 0.05), and transcripts destabilized upon SORBS2 knockdown (n = 2560; fold change down > 1.1 after α-amanitin treatment in
shSORBS2 vs control cells). c Pie chart showing the subcellular locations of proteins translated by SORBS2-stabilized transcripts. d Genes encoding
secreting proteins translated by SORBS2-stabilized transcripts
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depolarization, kinetochore assembly and organization,
metaphase plate congression, establishment of chromo-
some localization, negative regulation of intrinsic apop-
totic signaling pathway in response to DNA damage, and
regulation of transcription involved in G1/S transition of
mitotic cell cycle (Additional file 5: Table S4). In addition,
gene ontology enrichment analysis of KEGG pathways in-
dicated that these genes are enriched in pathways includ-
ing the FoxO signaling pathway, long-term depression,
metabolism of xenobiotics by cytochrome P450, adherens
junction, transcriptional misregulation in cancer, proteo-
glycans in cancer, pathways in cancer, and the cGMP-PKG
signaling pathway (Additional file 5: Table S4). These ob-
servations indicate that SORBS2 binds to and stabilizes
the transcripts in ovarian cancer cells.
WFDC1 and IL-17D mRNAs are bound by SORBS2 and
destabilized by SORBS2 depletion
Among the 91 gene transcripts potentially bound and
stabilized by SORBS2, seven transcripts that encode se-
creted proteins attracted our attention since we focus on
potential interactions between ovarian cancer cells and
the tumor microenvironment during the metastatic
process (Fig. 3c, d). This gene set was comprised of
BMPER, C1QTNF1, TFPI, WNT9A, WFDC1, LGALS3BP,
and IL-17D (Fig. 3d). The steady-state levels of these
seven transcripts were assessed in two SORBS2-
knockdown ovarian cancer cell lines and we identified
the mRNAs of two genes, WFDC1 and IL-17D, as exhi-
biting reduced steady-state levels upon SORBS2 knock-
down in both cell lines (Additional file 2: Figure S10a,
b). The intracellular protein levels of WFDC1 and IL-
17D and their relative concentrations in conditioned
media were also found to be decreased in SORBS2-
depleted cells (Additional file 2: Figure S10e, f ). More-
over, we found that SORBS2 binds the 3′ UTRs ofWFDC1
and IL-17D, suggesting that SORBS2 may enhance the sta-
bility of these transcripts through direct interactions with
their 3′ UTRs (Additional file 2: Figure S9c). To further val-
idate this observation, the reduced stability of WFDC1 and
IL-17D transcripts upon SORBS2 knockdown was verified
by quantitative reverse transcription PCR (qRT-PCR), using
α-amanitin to inhibit transcription (Fig. 4a). To validate the
stabilization of these two transcripts by SORBS2 using an
Fig. 4 SORBS2 depletion destabilizes transcripts of WFDC1 and IL-17D, which are correlated with clinical outcome in ovarian cancer. a qRT-PCR of
WFDC1 and IL-17D in control A2780s and control SKOV-3 ovarian cancer cells and SOBRS2-depleted A2780s and SKOV-3 ovarian cancer cells at 0
and 9 h after α-amanitin treatment. 18S was used as an endogenous control. b qRT-PCR of WFDC1 and IL-17D in A2780s shSORBS2 and shCTRL
cells at the times indicated after treatment of cells with DRB. c Kaplan-Meier curve showing overall survival of ovarian cancer patients with tumors
expressing high (red) or low (black) levels of WFDC1 and IL-17D. Data are shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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independent assay of transcription inhibition, we used
dichlorobenzimidazole 1-β-D-ribofuranoside (DRB), an in-
hibitor of CDK9. Following DRB treatment, WFDC1 and
IL-17D transcripts exhibited shorter half-lives in SORBS2-
depleted cells relative to control cells (Fig. 4b). Moreover, in
SORBS2-overexpressing cells, we observed longer half lives
of WFDC1 and IL-17D transcripts compared with control
cells (Additional file 2: Figure S11a, b). As certain classes of
RBPs have a role in modulating poly(A) site selection [15],
and considering the location of the SORBS2-binding sites
near the 3′ end of the coding sequence stop codons in the
WFDC1 and IL-17D transcripts, SORBS2 might regulate
the stability of these transcripts through modulation of
poly(A) site choice. Therefore, we further examined
whether the 3′ UTR lengths of the WFDC1 and IL-17D
transcripts were altered in SORBS2-knockdown and in
SORBS2-overexpressing cells. We did not find a significant
difference in the 3′ UTR lengths of these transcripts upon
SORBS2 depletion (Additional file 2: Figure S10c, d). In
addition, we did not notice any changes in the 3′
UTR lengths of the WFDC1 and IL-17D transcripts in
SORBS2-overexpressing cells compared with control
cells (Additional file 2: Figure S11c, d). These results
indicates that, in ovarian cancer cells, SORBS2 binds
to the 3′ UTRs of WFDC1 and IL-17D transcripts
and promotes their stability without affecting the
lengths of 3′ UTRs.
SORBS2-bound targets WFDC1 and IL-17D suppress
metastatic colonization in ovarian cancer cells
Given that SORBS2 knockdown reduced the stability
and subsequent abundance of WFDC1 and IL-17D tran-
scripts, we attempted to characterize the functional roles
of these two genes in metastatic colonization of ovarian
cancer cells. We first performed Kaplan-Meier analysis
in ovarian cancer patients of TCGA dataset. Results
showed that the expression of WFDC1 (P = 0.0016, haz-
ard ratio (HR) = 0.66 (0.51–0.86)) and IL-17D (P =
0.019, HR = 0.7(0.52–0.95)) was positively correlated
with overall survival of ovarian cancer patients in TCGA
dataset (Fig. 4c). We next assessed whether the expres-
sion of SORBS2 is correlated with the expression of
WFDC1 or IL-17D in clinical specimens. Immunohisto-
chemistry analysis revealed that in ovarian cancer speci-
mens with high SORBS2 expression, expression of
WFDC1 and IL-17D was also reduced in both primary
and metastatic foci of ovarian cancer (Fig. 5a and
Additional file 2: Figure S12a). Moreover, we examined
the relative concentrations of WFDC1 and IL-17D in the
ascites of ovarian cancer patients in low and high SORBS2
tissues. Interestingly, we also observed that the relative
concentration of both WFDC1 and IL-17D was signifi-
cantly lower in SORBS2-low patients compared with that
in SORBS2-high patients (Additional file 2: Figure S12b).
Oncomine database analysis revealed that in the Anglesio
cohort (GSE12172), the expression of WFDC1 was signifi-
cantly lower in metastatic sites of ovarian cancer com-
pared with primary sites (P = 0.014). In addition, in the
Gilks cohort (GSE3208), the expression of IL-17D was sig-
nificantly lower in stage I and II ovarian cancer patients
compared with stage III and IV ovarian cancer patients (P
= 0.023; Fig. 5b).
We next determined whether reconstituting the ex-
pression of these genes in cells depleted of SORBS2
could reverse the enhanced metastatic phenotype of
ovarian cancer in vitro and in vivo. We observed that
stable overexpression of either WFDC1 or IL-17D or a
combination of both (Additional file 2: Figure S13a, b)
significantly decreased the invasive capacity of SORBS2-
depleted ovarian cancer cells compared with control, re-
vealed by Transwell chamber analysis (Fig. 5c) and
wound healing analysis (Fig. 5d). Moreover, the in vivo
metastatic colonization potential of SORBS2-depleted
ovarian cancer cells was also remarkably reduced after
overexpression of either WFDC1 or IL-17D or a com-
bination of them (Fig. 5e). In detail, reconstituting the
expression of either WFDC1 or IL-17D or a combin-
ation of both in SORBS2-knockdown ovarian cancer
cells significantly reduced the number of metastatic nod-
ules (Additional file 2: Figure S13c) and ascites volume
compared with control SORBS2-knockdown ovarian
cancer cells in vivo (Additional file 2: Figure S13d).
These findings revealed that overexpression of either
WFDC1 or IL-17D or a combination of them is suffi-
cient to repress the metastatic colonization of SORBS2-
depleted ovarian cancer cells in vivo as well as suppress
migration in vitro.
SORBS2 recognizes and stabilizes these metastasis-
suppressive transcripts via its ZnF_C2H2 domain
SORBS2 primarily has three types of domain: one SoHo
domain, one ZnF_C2H2 domain, and three SH3 do-
mains. We created three deletion mutants: a SoHo mu-
tant (termed ΔSoHo), containing only the ZnF_C2H2
domain and three SH3 domains and devoid of the SoHo
domain; a Znf mutant (termed ΔZnf), containing only
the SoHo domain and three SH3 domains and lacking
the ZnF_C2H2 domain; a SH3 mutant (termed ΔSH3),
containing only the SoHo domain and one ZnF_C2H2
domain and devoid of the three SH3 domains (Fig. 6a).
Human ovarian cancer cell line A2780s was transfected
with wild-type (WT) SORBS2, ΔSoHo, ΔZnf, and ΔSH3
plasmids to determine which domain is key for SORBS2
to recognize and stabilize the abovementioned tran-
scripts. Interestingly, we found that enforced expression
of ΔSoHo and ΔSH3 plasmids significantly suppressed
ovarian cancer migration in vitro compared to WT
SORBS2 protein while enforced expression of ΔZnf
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plasmids did not inhibit ovarian cancer cell migration
(Fig. 6b). Moreover, we observed significantly decreased
numbers of metastatic nodules and reduced volume of
ascites of mice inoculated with A2780s cells with
enforced expression of ΔSoHo and ΔSH3 plasmids, simi-
lar to A2780s cells with enforced expression of WT
SORBS2. By contrast, no significant reduction in the
number of metastatic nodules and ascites volume in
mice inoculated with A2780s cells with enforced expres-
sion of the ΔZnf plasmid was observed compared with
control A2780s cells (Fig. 6c, d). In addition, we deter-
mined whether the ZnF_C2H2 domain was indispens-
able for SORBS2-mediated stabilization of WFDC1 and
IL-17D. We found that the expression level of both
WFDC1 and IL-17D in A2780s cells with enforced ex-
pression of ΔSoHo and ΔSH3 plasmids was comparable
to that in A2780s cells with enforced expression of WT
SORBS2. However, both WFDC1 and IL-17D expression
levels were remarkably decreased in A2780s cells with
enforced expression of the ΔZnf plasmid (Fig. 6e, f ).
Fig. 5 SORBS2 knockdown-induced enhanced ovarian cancer metastasis can be reversed by enforced expression of WFDC1 and IL-17D alone or
combined. a Immunohistochemistry analysis of WFDC1 and IL-17D expression in SORBS2-low and SORBS2-high metastatic tissues of ovarian cancer. b
WFDC1 and IL-17D expression at different clinical stages of ovarian cancer in the Oncomine database. c WFDC1, IL-17D, and a combination of WFDC1
and IL-17D were stably overexpressed in shSORBS2 A2780s cells. Transwell chamber assays were performed with these cells. d WFDC1, IL-17D, and a
combination of WFDC1 and IL-17D were stably overexpressed in SORBS2-depleted A2780s cells. Wound healing assays were performed with these
cells. e Representative photographs of peritoneal metastasis of WFDC1-overexpressed, IL-17D-overexpressed and, WFDC1/IL-17D-overexpressed
SORBS2-depleted A2780s ovarian cancer cells compared with control SORBS2-depleted A2780s cells and shCTRL-treated A2780s cells 4 weeks
post-inoculation. Data are shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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These data indicate that, among the three domains, only
the ZnF_C2H2 domain is functional in binding to and
stabilizing target mRNAs by SORBS2.
SORBS2 depletion-induced secretome alterations are
associated with monocyte to MDSC and M2-like
macrophage polarization
As WFDC1 and IL-17D are secreted factors released by
SORBS2-low ovarian cancer cells, we wondered whether
they have any impact on the tumor microenvironment
upon ovarian cancer metastasis. Specifically, we focused
on the pro-cancer immunomodulatory role of SORBS2
and its bound targets WFDC1 and IL-17D. RNA sequen-
cing (RNA-seq) data from a cohort of 354 high grade
serous ovarian carcinoma (HGS-OvCa) patients (Cancer
Genome Atlas Research Network, 2014), obtained from
TCGA (https://cancergenome.nih.gov/), to bioinformatic
co-expression analysis focusing on immune cell markers
and cytokines. Interestingly, SORBS2 expression showed
a significant negative correlation with the expression of
11 M2 myeloid cell markers and cytokines associated
with their expansion (Fig. 7a). Next, we determined
whether an association exists between the expression of
SORBS2 and the expression of WFDC1 or IL-17D in
TCGA dataset. We found a positive correlation between
SORBS2 expression and WFDC1 expression (Fig. 7b) as
well as between SORBS2 expression and IL-17D expres-
sion (Fig. 7c). We further analyzed combined SORBS2
and WFDC1 high versus low expression levels as well as
SORBS2 and IL-17D high versus low expression levels
with respect to co-expression with factors involved in
M2-like cell signaling. Corresponding with a decisive
role for SORBS2-stablized WFDC1 and IL-17D in gener-
ating a metastasis-suppressing phenotype of ovarian can-
cer, the expression levels of 8 and 14 M2 markers and
cytokines also showed significant negative correlation
Fig. 6 SORBS2 recognizes and stabilizes these metastasis-suppressive transcripts via its ZnF_C2H2 domain. a SORBS2 with its binding domains and
the respective mutants. b Transwell invasion assays were performed in control A2780s cells and A2780s cells with enforced expression of WT SORBS2,
ΔSoHo, ΔSH3, and ΔZnf plasmids. c Peritoneal metastatic nodule number in mice inoculated with control A2780s cells and A2780s cells with enforced
expression of WT SORBS2, ΔSoHo, ΔSH3, and ΔZnf plasmids 4 weeks post-inoculation. d Ascites volume in mice inoculated with control A2780s cells
and A2780s cells with enforced expression of WT SORBS2, ΔSoHo, ΔSH3, and ΔZnf plasmids 4 weeks post-inoculation. e Relative mRNA levels of WFDC1
in control A2780s cells and A2780s cells with enforced expression of WT SORBS2, ΔSoHo, ΔSH3, and ΔZnf plasmids. f Relative mRNA levels of IL-17D in
control A2780s cells and A2780s cells with enforced expression of WT SORBS2, ΔSoHo, ΔSH3, and ΔZnf plasmids. Data are shown as mean ± SEM.
*P < 0.05, **P < 0.01
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with combined SORBS2/WFDC1 (Fig. 7d) and SORBS2/
IL-17D levels (Fig. 7e), respectively, constituting a
tumor-suppressive immune microenvironment.
In this context, we further investigated whether the
SORBS2 depletion-induced secretome might functionally
affect immune cell polarization. To this end, human
healthy donor CD14+ cells were cultured with condi-
tioned media of control or SORBS2-knockdown A2780s
ovarian cancer cells (Fig. 8a). Interestingly, conditioned
media of SORBS2-depleted A2780s cells polarized
healthy donor CD14+ cells toward an HLA-DRlo/neg
phenotype, an immune cell population equivalent to mur-
ine CD11b + GR1+ MDSCs, compared with conditioned
media of control A2780s cells. However, conditioned media
from either WFDC1 or IL-17D overexpressed, SORBS2-
depleted ovarian cancer cells significantly reduced the
amount of HLA-DRlo/neg CD14+ cells (Fig. 8b). Further-
more, HLA-DRlo/neg as well as HLA-DR+ cells displayed
increased levels of CD206 expression after incubation of
conditioned media of SORBS2-depleted A2780s cells com-
pared with conditioned media of control A2780s cells, indi-
cating polarization toward MDSCs and fully differentiated
M2 macrophage phenotypes, respectively (Fig. 8c, d). By
contrast, conditioned media from either WFDC1 or IL-17D
overexpressed SORBS2-depleted ovarian cancer cells could
obviously reverse this process (Fig. 8c, d). Therefore,
SORBS2 depletion-induced secretome alterations are asso-
ciated with monocyte to MDSC and M2-like macrophage
polarization, which indicates an immunomodulatory role of
SORBS2 and its stabilized transcripts in the tumor
microenvironment.
Cancer-derived SORBS2-stabilized secretome suppresses
tumor metastasis and recruitment of tumor-supportive
infiltrates in vivo
As the full extent of the effect of the cancer-derived
SORBS2-stabilized secretome on immune cell infiltration
can most suitably be assessed in immune-proficient mice,
we next made use of the established ID-8 ovarian cancer
peritoneal metastasis mouse model. We first established a
SORBS2-knockdown ID-8 cell line, WFDC1-overexpressing
SORBS2-knockdown ID-8 cell line, and IL-17D-
overexpressing SORBS2-knockdown ID-8 cell line. The
transfection efficacy was evaluated by measuring the mRNA
levels of each gene (Additional file 2: Figure S14a). We next
performed intrabursal injection of these cell lines in C57BL/
Fig. 7 WFDC1 and IL-17D correlate with a tumor-suppressive immune profile in ovarian cancer patients. a Heatmap of immune-related genes significantly
co-expressed (P = 0.01) with SORBS2, showing log2 expression Z scores for 20% of samples with highest or lowest SORBS2 expression. b Correlation data
for SORBS2 versus WFDC1 expression in TCGA dataset. The statistical significance of correlations was determined using Pearson’s correlation coefficient. c
Correlation data for SORBS2 versus IL-17D expression in TCGA dataset. The linear regression curve is shown as a black line for significant correlations. d As
in a for 50% of samples with the highest or lowest combined SORBS2 and WFDC1 expression. e As in b for samples with highest or lowest combined
SORBS2 and IL-17D expression
Zhao et al. Genome Biology  (2018) 19:35 Page 11 of 20
6 immune-competent mice. At sacrifice, we found that the
SORBS2-knockdown ID-8 cell group demonstrated signifi-
cantly more metastatic nodules (Additional file 2: Figure
S14b, c) and ascites volume (Additional file 2: Figure S14d, e)
compared with the control group. Moreover, reconstituting
the expression of either WFDC1 or IL-17D in the SORBS2-
knockdown ID-8 cell group significantly reduced the number
of metastatic nodules (Additional file 2: Figure S14b, c) and
ascites volume (Additional file 2: Figure S14d, e) compared
with the SORBS2-knockdown ID-8 cell group. These find-
ings are consistent with our observations in immune-
deficient mouse models.
In line with a functional involvement of alternatively
activated myeloid cells in influencing tumor burden, the
number of CD11b + GR1+ myeloid infiltrates within the
tumor tissue of the SORBS2-knockdown group were sig-
nificantly increased compared with those in the control
ID-8 group (Fig. 9a, b). Moreover, the expression of
CD206 on these myeloid infiltrates also significantly in-
creased in the SORBS2-knockdown group compared
with the control ID-8 group (Fig. 9c, d). However, recon-
stituting the expression of either WFDC1 or IL-17D in
the SORBS2-knockdown ID-8 cell group significantly re-
duced the content of CD11b + GR1+ myeloid infiltrates
as well as the expression of CD206 in these myeloid in-
filtrates compared with those in the SORBS2-
knockdown ID-8 cell group (Fig. 9a–d). Thus, we con-
clude that the cancer-derived SORBS2-stabilized secre-
tome could potently suppress ovarian cancer metastasis
and modulate the accumulation of tumor-promoting
myeloid cells in vivo (Fig. 9e, f ).
Discussion
Surgical cytoreduction of advanced-stage ovarian cancer
has long been considered an important tenet of effective
management of this disease. Although the sequence of
chemotherapy and surgical intervention is debated, there
is broad consensus that integration of the two modalities
represents the best initial strategy for women with meta-
static ovarian cancer [1, 16]. So far, the molecular mech-
anisms underlying the metastatic process of ovarian
cancer remain largely unknown. In this study, we used a
combination of computational, biochemical, and func-
tional approaches to identify key molecular events that
underly the metastatic process of ovarian cancer and
characterize a novel post-transcriptional network that
controls ovarian cancer metastatic colonization through
SORBS2-mediated transcript stabilization.
Precise regulation of RNA metabolism is instrumental
to the generation of biological complexity in both nor-
mal and pathological circumstances. The concerted ac-
tion of RBPs regulate the spatial, temporal, and
Fig. 8 SORBS2 depletion-induced secretome alterations are associated with monocyte to MDSC and M2-like macrophage polarization in human. a A
schematic model of the monocyte polarization protocol. CD14+ cells were isolated from healthy donor peripheral blood mononuclear cells (PBMCs)
via magnetic CD14+ microbeads and incubated with conditioned medium (CM) from control A2780s ovarian cancer cells, SORBS2-depleted A2780s
ovarian cancer cells, WFDC1-overexpressing SORBS2-depleted A2780s ovarian cancer cells, and IL-17D-overexpressing SORBS2-depleted A2780s ovarian
cancer cells. After 48 h, treated myeloid cells were stained with fluorochrome-labeled antibodies against HLA-DR, CD14, and CD206 and analyzed by
flow cytometry. Data are presented as fold change in HLA-DRlo/neg CD14+ cells (b), HLA-DRlo/neg, CD14+, CD206+ cells (c), or HLA-DR+, CD14+
CD206+ macrophages (d) upon conditioned media incubation. Data are shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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Fig. 9 (See legend on next page.)
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functional dynamics of the transcriptome via alternative
splicing, alternative polyadenylation, and transcript sta-
bility [17]. While dysregulation of RNA metabolism via
abnormal microRNA expression is relatively well estab-
lished, accumulating evidence indicates a vital role also
for RBPs in the development and progression of cancer.
However, the functional role of this group of proteins in
ovarian cancer has not been reported. In this study, we
elucidate a mechanism through which the RBP SORBS2
mediates its suppressive effect in ovarian cancer meta-
static colonization. SORBS2 enhances the stability of the
transcripts by binding to the 3′ UTRs of target mRNAs,
without influencing the lengths of those 3′ UTRs.
SORBS2, also known as Arg/c-Abl kinase binding pro-
tein 2 (ArgBP2), is an adapter protein that could interact
with multiple actin regulatory proteins, including Arg, c-
Abl, Vinculin, Paxillin, WAVE, c-Cbl, Pyk2, PKB, PAK1,
α-actinin, 14–3-3, and SAPAP, which can be generally
grouped into cell adhesion molecules and regulators and
effectors of small GTPases [18]. Previous research has
highlighted its functional role in disease states, such as
intellectual disability, gastric cancer, sepsis-associated
cardiac dysfunction, and facioscapulohumeral dystrophy
[19–22]. However, its role as an RBP has rarely been re-
ported. Like other RBPs which either directly modulate
transcript stability or regulate alternative splicing pat-
terns, SORBS2 could impact gene expression and pheno-
typic output of ovarian cancer cells in part through
enhancing the stability of a subset of gene transcripts,
especially the metastasis suppressor WFDC1 and IL-17D
transcripts, and interacting with their 3′ UTRs.
WFDC1 and IL-17D are examples of SORBS2-bound
transcripts that are directly regulated by SORBS2 and
act as metastasis suppressors. WAP four-disulfide core
domain 1 (WFDC1) is a 24 kDa secreted protein
encoded by the WFDC1 gene [23]. It is part of the WAP
domain-containing family of proteins consisting of small
secreted immunomodulatory factors that are being in-
creasingly recognized as important regulators of cell and
tumor growth. Previous reports have demonstrated that
WFDC1 expression was dramatically downregulated in
highly prolific mesenchymal cells and in a number of
cancers, including fibrosarcomas, and in tumors of the
lung, bladder, prostate, and brain [24]. Moreover, overex-
pression of WFDC1 inhibited the growth rate of the
fibrosarcoma HT1080 cell line. In line with these find-
ings, our study also proved that overexpression of
WFDC1 in SORBS2-depleted ovarian cancer cells sig-
nificantly impaired their metastatic potential. IL-17D,
which belongs to the IL-17 family of cytokines, is a cyto-
kine whose function is not well annotated. Although
similar to IL-17C, it is known to be expressed outside
the immune system and could stimulate human umbil-
ical vein endothelial cells to produce IL-6, IL-8, and
GM-CS [25]. Recently, its role in tumor development
and progression has been investigated. O’Sullivan et al.
[26] reported that IL-17D was highly expressed in cer-
tain unedited tumors but not in edited mouse tumor cell
lines. Moreover, forced expression of IL-17D in edited
tumor cells induced rejection by stimulating MCP-1 pro-
duction from tumor endothelial cells, resulting in the re-
cruitment of natural killer (NK) cells. NK cells promoted
M1 macrophage development and adaptive immune re-
sponses. IL-17D expression was also decreased in certain
high-grade and metastatic human tumors, suggesting
that it can be targeted for tumor immune therapy. Our
study demonstrated that forced expression of IL-17D in
SORBS2-depleted ovarian cancer cells could also signifi-
cantly reduce ovarian cancer metastatic colonization.
Thus, SORBS2-bound transcripts of WFDC1 and IL-17D
served as potent metastatic suppressors in ovarian cancer.
As WFDC1 and IL-17D are secreted factors and are
reported to be immunomodulatory, we further focused
on the immunomodulatory role of these two genes in
ovarian cancer metastasis. Ressler et al. [27] showed that
Wfdc1-null mice infected with influenza A exhibited
2.75-log-fold lower viral titer relative to control mice.
Wfdc1-null infected lungs exhibited elevated macrophage
(See figure on previous page.)
Fig. 9 Cancer-derived SORBS2-stabilized secretome suppresses tumor metastasis and recruitment of tumor-supportive infiltrates in vivo. a The
percentage of CD11b + GR-1+ cells in the CD45+ cells of the metastatic nodules of C57BL/6 mice intrabursally inoculated with control ID-8 cells,
SORBS2-knockdown ID-8 cells, and WFDC1 overexpressing SORBS2-knockdown ID-8 cells. n = 6 in each group. b The percentage of CD11b +
GR-1+ cells in the CD45+ cells of the metastatic nodules of C57BL/6 mice intrabursally inoculated with control ID-8 cells, SORBS2-knockdown ID-8
cells, and IL-17D-overexpressing SORBS2-knockdown ID-8 cells. n = 6 in each group. c The percentage of CD206+ cells in the CD11b + GR-1+ cells
of the metastatic nodules of C57BL/6 mice intrabursally inoculated with control ID-8 cells, SORBS2-knockdown ID-8 cells, and WFDC1-
overexpressing SORBS2-knockdown ID-8 cells. n = 6 in each group. d The percentage of CD206+ cells in the CD11b + GR-1+ cells of the metastatic
nodules of C57BL/6 mice intrabursally inoculated with control ID-8 cells, SORBS2-knockdown ID-8 cells, and IL-17D-overexpressing SORBS2-knockdown
ID-8 cells. n = 6 in each group. e At the global level, SORBS2 could bind different kinds of mRNAs and stabilize a proportion of these mRNAs. The net
effect of progression-promoting and -inhibiting alterations determine whether SORBS2 loss is beneficial for ovarian cancer metastatic colonization. f At
the target mRNA level, SORBS2 could stabilize the transcripts of WFDC1 and IL-17D, which leads to overexpression of these secreting factors. On one
hand, they could partly suppress ovarian cancer metastasis; on the other hand, they could inhibit the polarization of monocytes towards MDSCs and
M2-like macrophages, which is important for a immune suppressive tumor microenvironment favorable for ovarian cancer metastatic colonization.
Data are shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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levels and deposition of osteopontin, a potent macrophage
chemokine. In wounding studies, Wfdc1-null mice exhib-
ited an elevated rate of skin closure, and this too was corre-
lated with elevated deposition of osteopontin and
macrophage recruitment. Wfdc1-null fibroblasts exhibited
impaired spheroid formation, elevated adhesion to fibro-
nectin, and an increased rate of wound closure in vitro.
This was reversed by neutralizing antibody to osteopontin.
These data suggest that WFDC1 is a core component of
the immunomodulatory network. Moreover, recent re-
search has also recognized the key position of IL-17D in
modulating the immune system. Apart from O'Sullivan
et al.’s observation that IL-117D mediates tumor rejection
through recruitment of natural killer cells, Saddawi-
Konefka et al. [28] also demonstrated that the transcription
factor nuclear factor erythroid-derived 2-like 2 (Nrf2) could
induce the expression of IL-17D in cancer cell lines. Ex-
pression of IL-17D in tumors and virally infected cells is es-
sential for optimal protection of the host as il17d(−/−) mice
experienced a higher incidence of tumors and exacerbated
viral infections compared to WT animals. Moreover, acti-
vating Nrf2 to induce IL-17D in established tumors led to
NK cell-dependent tumor regression. These data demon-
strate that IL-17D effects a form of extrinsic stress surveil-
lance by inducing antitumor immunity. Our study shows
that supernatants of both WFDC1- and IL-17D-
overexpressed, SORBS2-depleted ovarian cancer cells sig-
nificantly reduced the amount of HLA-DRlo/neg CD14+
cells in vitro. Moreover, in an immuno-proficient model,
we also found that WFDC1 and IL-17D could potently
suppress ovarian cancer metastasis and are able to inhibit
the accumulation of tumor-promoting myeloid cells.
Therefore, it is conceivable that WFDC1 and IL-17D, as
part of a SORBS2-stablized secretome, could play a crucial
role in modulating the polarization of myeloid cells within
the tumor microenvironment, which remodel it towards a
tumor-suppressive immune milieu.
Conclusions
Our study illustrates a novel RBP-based post-transcriptional
network that links cancer progression and immunomodula-
tion within the tumor microenvironment. The transcripts,
in particular WFDC1 and IL-17D, encode secreting factors
that not only limit the metastasis of ovarian cancer, but also
remodel the tumor immune microenvironment towards
tumor suppression. Our findings have identified a functional
role of SORBS2 and its stabilized transcripts in ovarian can-
cer progression, deepening our understanding of the mo-
lecular complexities of ovarian cancer metastasis.
Methods
Bioinformatics analysis
As a starting point for identifying RBPs required for
ovarian cancer aggressiveness, we first collected a list of
1345 genes encoding RBPs from high-throughput
screens by Castello et al. [29], Baltz et al. [30], and Ray
et al. [31], human orthologs of RBPs identified in mouse
embryonic stem cells by Kwon et al. [32], and RBPs re-
ported in RBPDB [33]. Proteins annotated in
ENSEMBL’s human genome build which were not iden-
tified as RBPs were considered as non-RBPs. To generate
a cancer-relevant “high priority” subset of RBP genes
(out of the 1345 genes we classified as RBPs), we first
identified those genes whose expression are significantly
associated with the cancerous state, stemness, or metas-
tasis in ovarian cancer. Genes associated with the can-
cerous state were obtained by analyzing the differential
gene expression that profiled normal ovary tissues and
primary ovarian tumors in GSE14407 [9]. Genes associ-
ated with stemness were obtained by analyzing the dif-
ferent gene profiles between ovarian cancer spheroids
and ovarian cancer monolayers in GSE53759 [11]. To
identify the genes associated with metastasis, we ana-
lyzed the differential gene expression profiles between
nine matched pairs of primary ovarian tumors and me-
tastases from the omentum in GSE30587 [10]. In each
dataset, the gene expression profiles were classified be-
tween the two groups and for each group the log2 me-
dian centered intensity for each gene was determined. A
P value associated with the significance of the difference
between the two groups was calculated with the Stu-
dent’s t-test. From all these genes with a P value< 0.05,
we identified those that are in the top 10% of the most
down-regulated RBP genes in each dataset. To generate
the final high priority set of 145 genes that was screened,
three categories of genes were selected: (1) genes scoring
in all three analyses; (2) the most significantly scoring
5% of genes in any one category; and (3) the most sig-
nificantly scoring 10% of genes in any two categories.
Subsequently, this set of RNA binding genes was
searched for degree of deletion or amplification in
TCGA high-grade serous ovarian carcinoma (HGS-
OvCa) dataset. Only those with deletion of more than
5% were selected for further functional validation.
Ovarian cancer expression and survival analysis in
datasets
The Oncomine database was searched to compare the
expression levels of different genes in ovarian cancer
datasets. Kaplan-Meier survival analyses for disease out-
comes in the Australian Ovarian Cancer Study (AOCS)
dataset (GSE9891, n = 285) were conducted using the
online database (http://www.kmplot.com/). P values
were calculated with log-rank (Mantel–Cox) test. Pa-
tients were stratified into “low” and “high” expression
based on autoselect best cutoff in the database. The
CSIOVDB database was also queried to validate the ex-
pression of different genes and their correlation with
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clinical staging, pathological differentiation degree, and
clinical outcome of ovarian cancer patients.
Reagents, cell culture, and cell transfection
α-Amanitin, DRB, and propidium iodide were purchased
from Sigma. The concentration of α-amanitin used was
10 μg/mL and the final concentration of DRB used
reached 100 μM. Antibodies used are as follows:
SORBS2 (Abcam, ab73444), cleaved caspase 3 (Abcam,
ab13847), WFDC1 (Abcam, ab126846, for western blot-
ting analysis), WFDC1 (Sigma, HPA031411, for IHC
analysis), IL-17D (Abcam, ab77185), Ki-67(Abcam,
ab15580), Flag (Sigma, F3165), β-actin (Abcam, ab8226),
HLA-DR (human; BD Bioscience, 556,643), CD14 (hu-
man; BD Bioscience, 555,397), CD206 (human; BioLegend,
321,121), CD45 (murine; BioLegend, 103,127), CD11b
(murine; BioLegend, 101,230), GR-1 (murine; BioLegend,
108,416), CD206 (murine; BioLegend, 141,703).
All cell lines were maintained at 37 °C and 5% CO2.
The human ovarian cancer cell lines SKOV3, CAOV3,
COV434, COV644, COV362, and COV504 were cul-
tured in Dulbecco’s modified Eagle medium supple-
mented with 10% fetal bovine serum (FBS), 2 mM L-
glutamine, 1 mM sodium pyruvate, and 100 U/ml
penicillin-streptomycin (both from Gibco-BRL, Grand
Island, NY, USA). The human ovarian cancer cell lines
A2780S, OVSAHO, OVTOKO, OV56, COLO-720E,
OVISE, OV90, KURAMOCHI, OVCAR4, and OVCAR3
were cultured in RPMI-1640 containing 10% FBS and
100 U/ml penicillin-streptomycin (both from Gibco-
BRL, Grand Island, NY, USA). The mouse ovarian can-
cer cell line ID-8 was cultured in Dulbecco’s modified
Eagle medium supplemented with 10% FBS, 2 mM L-
glutamine, 1 mM sodium pyruvate, and 100 U/ml
penicillin-streptomycin (both from Gibco-BRL, Grand
Island, NY, USA). Cell lines received in 2014 were tested
for authenticity in 2016 using short tandem repeat
(STR) genotyping.
Based upon the shRNA design principle, oligonucleo-
tide sequences of SORBS2 and respective corresponding
nontargeting negative control (NC) shRNAs were de-
signed by OBiO Technology (Shanghai, China), which
are as follows: sh1-SORBS2, forward, 5′-CGCTAA-
CATCTGTGAAGAGcTCAAGAGACTCTTCACAGAT
GTTAGCG-3′, reverse, 5′-CGCTAACATCTGTGAA-
GAGTCTCTTGAGCTCTTCACAGATGTTAGCG-3′;
sh2-SORBS2, forward, 5′-TGCAAAGTTCTCCAAACC
TCTCAAGAGAAGGTTTGGAGAACTTTGCA-3′, re-
verse, 5′-TGCAAAGTTCTCCAAACCTTCTCTTGAgA
GGTTTGGAGAACTTTGCA-3′. They were separately
transfected into cells using Lipofectamine 3000 (Invitro-
gen) according to the manufacturer’s instructions. siRNA
oligonucleotides with specificity for BTF3, SORBS2,
CIRBP, and MEX3D and respective corresponding
nontargeting control siRNAs were obtained from Gene-
Pharma. They were separately transfected into cells
using Lipofectamine RNAiMAX (Invitrogen) according
to the manufacturer’s instructions. The full-length hu-
man Flag-tagged SORBS2 plasmid, IL-17D plasmid,
WFDC1 plasmid, and the three SORBS2 mutant plas-
mids were purchased from Gene Copoeia (Guangzhou,
China). The plasmids were designed based on the cDNA
sequence of SORBS2 (GenBank™ accession number
NM_021069.4), IL-17D (GenBank™ accession number
NM_138284.1), and WFDC1 (GenBank™ accession num-
ber NM_021197.3). They were separately transfected
into cells using Lipofectamine 3000 (Invitrogen) accord-
ing to the manufacturer’s instructions.
Patients and specimens
De novo serous ovarian cancer patients and normal
ovarian surface tissue specimens as controls were col-
lected from West China Second Hospital, Sichuan Uni-
versity. The ascites samples of ovarian cancer patients
were also obtained from West China Second Hospital,
Sichuan University. All of these samples were examined
by experienced pathologists who confirmed the diagno-
sis of disease samples.
Immunohistochemistry
Paraffin-embedded normal ovary and ovarian cancer
specimens from West China Second Hospital, Sichuan
University were used for immunohistochemistry. Immu-
nohistochemistry was performed utilizing primary anti-
bodies listed in Additional file 6: Table S5 as previously
described [34]. Ten random images per section were
captured, and immunohistochemical staining positivity
was determined by calculating the percentage of positive
cells and immunostain intensity using Image-Pro Plus
version 6.0 (Media Cybernetics, Baltimore, MD). All
slides were evaluated by two independent pathologists in
a double-blinded manner. Any discrepancy between the
two evaluators was resolved by re-evaluation and open
deliberation until agreement was reached.
Immunoblotting
For immunoblotting, the whole cell lysates were pre-
pared as described previously [35]. Detailed information
on the primary antibodies used in immunoblotting ana-
lysis are listed in Additional file 6: Table S5. The signals
were quantified by QuantityOne software (Bio-Rad) and
β-actin was used as internal control.
An orthotopic intrabursal injection model of ovarian
cancer in mice
Animal studies were reviewed and approved by the Insti-
tutional Ethics Committee of Sichuan University. Female
athymic BALB/c nude mice (6–8 weeks old, 18–20 g
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each) were used to assess the peritoneal metastasis of
human ovarian cancer cell lines. Immuno-proficient fe-
male C57BL/6 mice (6–8 weeks old, 18–20 g each) were
used to assess the peritoneal metastasis of the mouse
ID-8 ovarian cancer cell line. An orthotopic model gen-
erated by intrabursal injection of ovarian cancer cell
lines in mice was conducted as previously described to
assess the peritoneal metastasis of ovarian cancer [35].
The number of metastatic nodules were counted and as-
cites volumes were measured at sacrifice.
Quantitative reverse transcription PCR
The mRNA level of each gene was measured via qRT-
PCR. Moreover, the change in 3′ UTR lengths of target
genes was also examined via qRT-PCR for increasingly
distal regions of target gene transcript 3′ UTRs relative
to the level of the coding sequence of each of the genes.
RNA was isolated using a total RNA isolation kit, in-
cluding an on-column DNase treatment (Norgen).
cDNA synthesis was carried out using the SuperScript
III reverse transcriptase kit using a mixture of oligodT
and random hexamers for priming (Life Technologies).
qRT–PCR was conducted with Fast SYBR Green master
mix (Applied Biosystems), and fluorescence was moni-
tored using a 7900HT Fast real-time instrument (Ap-
plied Biosystems). Data were analyzed using the ΔΔCt
method. Endogenous control transcripts were used for
normalization. Statistical significance was determined
using a one-tailed Student’s t-test. The sequences of the
primers used for all qRT–PCR assays are listed in
Additional file 7: Table S6.
Transwell invasion assay and wound healing assay
Transwell 24-well chambers (Corning) were used for
in vitro cell migration assays as described previously
[36]. Ten contiguous fields of each sample were exam-
ined to obtain a representative number of cells that had
migrated across the membrane. Wounds were scratched
in confluent cells using a pipette tip, and the cells were
then rinsed with medium to remove free-floating cells
and debris. Serum-free medium was subsequently added,
and culture plates were incubated at 37 °C for 2 days.
Wound healing was observed at 0 and 48 h within the
scrape line, and representative scrape lines for each cell
line were photographed.
Transcriptome sequencing
Whole-transcriptome sequencing libraries were con-
structed as described previously [37]. The libraries were
sequenced on the Illumina HiSeq platform (Novogen,
China). Reads were first trimmed to remove linker se-
quences and low-quality bases using Cutadapt (version
1.2.1). TopHat2 (version 2.0.8) was then used to map the
reads to the human transcriptome (RefSeq transcriptome
index hg19). Cufflinks (version 2.0.2) was then used to
estimate RPKM (reads per kilobase per million mapped
reads) values and compare the two samples. For each
group, two replicates were used for the analysis.
RIP sequencing
Cell lysates of A2780s ovarian cancer cells transiently
transfected with Flag-SORBS2 plasmid were used for the
RNA immunoprecipitation assay as described previously
[38]. An antibody raised against Flag was conjugated to
protein A Dynabeads (Life Technologies) and used to
immunoprecipitate endogenous SORBS2–RNA com-
plexes, with serum (IGG) as the control group. RNA was
extracted using Trizol following the manufacturer’s in-
structions (Invitrogen). rRNAs were removed from the
immunoprecipitated RNA and input RNA samples by
using Ribo-Zero™ rRNA Removal Kit (Illumina, San
Diego, CA, USA). RNA libraries were constructed by
using rRNA-depleted RNAs with TruSeq Stranded Total
RNA Library Prep Kit (Illumina, San Diego, CA, USA)
according to the manufacturer’s instructions. Libraries
were controlled for quality and quantified using the
BioAnalyzer 2100 system (Agilent Technologies, Inc.,
USA). Libraries (10 pM) were denatured as single-
stranded DNA molecules, captured on Illumina flow
cells, amplified in situ as clusters and finally sequenced
for 150 cycles on an Illumina HiSeq Sequencer accord-
ing to the manufacturer’s instructions at Cloudseq,
Shanghai in China.
Transcript stability assays
For the α-amanitin RNA sequencing data, A2780s
SORBS2-knockdown or control cells were treated with
10 μg/mL α-amanitin (Sigma). Nine hours after α-
amanitin treatment, RNA was isolated from the cells
using a total RNA isolation kit and subsequently sub-
jected to RNA sequencing. We compared and identified
the different mRNAs in shControl and sh1-SORBS2
samples at 0 and 9 h after α-amanitin treatment. The
differences between the sh1-SORBS2/shControl log fold
changes were used as a measure of stability. For valid-
ation of the RNA sequencing results, relative transcript
levels were assessed by qRT-PCR, and 18S was used as
an endogenous normalization control. Statistical signifi-
cance was determined using a one-tailed Student’s t-test.
Cells were seeded at 2 × 105 per well in six-well plates.
Eighteen hours after seeding, DRB (Sigma) was added to
the cells to a final concentration of 100 μM. RNA was
isolated at 0, 2, 4, 6, and 8 h after DRB addition using a
total RNA isolation kit with on-column DNase treat-
ment (Norgen). Relative levels of the transcripts of inter-
est were assessed by qRT-PCR, using 18S as the
endogenous control. Half-life calculations were done
using the formula t1/2 = ln 2/kdecay, where the decay
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constant was determined by plotting the data on a semi-
log scale and using nonlinear regression to find the best
fit line (Graphpad Prism version 6).
TCGA expression analysis
RNA-seq V2 level 3 data were downloaded for 354
HGS-OvCa samples from TCGA data portal using
TCGA biolinks package. The count values were trans-
formed to log2 counts per million using the voom function
from the limma R package. High and low composite groups
for SORBS2 (log fold change 0.75), SORBS2 and
WFDC1(log fold change 0.75), and SORBS2 and IL17D (log
fold change 0.75) were defined using overlapping samples
for both genes of a pair in the top and bottom 30% of ex-
pression values. Differentially expressed genes were deter-
mined using limma 0.75 fold change in expression between
the combined high and low groups and were filtered to a cu-
rated list of immune factors (Additional file 8: Table S7) for
visualization on heatmaps.
GSEA analysis was performed with the enrichment stat-
istic equal to weighted, and the metric for ranking genes
equal to signal-to-noise. Ovarian cancer gene expression
data were also obtained from TCGA dataset. False discov-
ery rate (FDR) q values of < 0.25 or nominal (NOM) P
values of < 0.05 were considered to be significant.
Flow cytometry
For flow cytometry-based apoptosis analysis, we lysed
the tumor tissues in each group, stained the cells with
the FITC Annexin V Apoptosis Detection Kit with PI
(BioLegend, 640,914), and then analyzed them by the
flow cytometry assay. For the cell cycle analysis, cells in
each group were stained by propidium iodide (Sigma,
P4170) and then analyzed by the flow cytometry assay.
Human CD14+ cells were isolated from healthy donor
peripheral blood mononuclear cells (PBMCs) using mag-
netic CD14+ microbeads and incubated with condi-
tioned media from A2780s ovarian cancer cells
transfected with shCtrl, SORBS2-depleted A2780s cells,
WFDC1-overexpressing and SORBS2-depleted A2780s
cells, and IL-17D-overexpressing and SORBS2-depleted
A2780s cells. After 48 h, treated myeloid cells were
stained with fluorochrome-labeled antibodies against
HLA-DR, CD14, and CD206 and analyzed by flow cy-
tometry. Mouse metastatic nodules were cut into small
pieces followed by passage through a 40-μM nylon filter
(BD). Red blood cells were lysed for 5 min at room
temperature (RT) in RBC lysis buffer (BioLegend). Cells
were then labeled with fixable viability dye eFluor780
(eBioscience) for 30 min in the dark at RT, followed by
Fc block (BD Biosciences). Antibodies used were against
CD45, CD11b, GR-1, and CD206. Detailed information
is shown in Additional file 6: Table S5.
Statistics
The data are presented as the means ± SD of three inde-
pendent experiments unless otherwise indicated. Graph-
Pad Prism (GraphPad Software Inc., La Jolla, CA) was
applied for data analysis with all data assessed for nor-
mal distribution and equal variance. The correlation
analysis was analyzed using a linear regression analysis.
Comparisons between two groups were performed with
Student’s t-test, and differences among multiple groups
were evaluated by one-way analysis of variance. The sur-
vival of different treatment groups were analyzed by
Kaplan-Meier analysis. Statistical significance is consid-
ered as P < 0.05.
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